The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.
Top 5 Upgrades:
Wolfe Research upgraded Paychex (PAYX) to Peer Perform from Underperform without a price target. The firm sees reduced estimate risk for the company amid stable employment trends.
UBS upgraded Union Pacific (UNP) to Buy from Neutral with a price target of $339, up from $310. The firm says its **** ysis of key customer markets points to a second year of strong volume growth in 2027 for Union Pacific.
Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy from Hold with a $9 price target after the FDA reaffirmed the pivotal study design for RP-A501 in Danon Disease, except for a recalibrated dose and prophylaxis.
Needham upgraded Similarweb (SMWB) to Buy from Hold with an $11 price target after meeting with management. Needham was encouraged by AI's potential to increase the value and consumption of Similarweb's data.
#needham #Research #union #pacific
Top 5 Upgrades:
Wolfe Research upgraded Paychex (PAYX) to Peer Perform from Underperform without a price target. The firm sees reduced estimate risk for the company amid stable employment trends.
UBS upgraded Union Pacific (UNP) to Buy from Neutral with a price target of $339, up from $310. The firm says its **** ysis of key customer markets points to a second year of strong volume growth in 2027 for Union Pacific.
Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy from Hold with a $9 price target after the FDA reaffirmed the pivotal study design for RP-A501 in Danon Disease, except for a recalibrated dose and prophylaxis.
Needham upgraded Similarweb (SMWB) to Buy from Hold with an $11 price target after meeting with management. Needham was encouraged by AI's potential to increase the value and consumption of Similarweb's data.
#needham #Research #union #pacific
12 hours ago
